Sinovac Biotech Ltd. was recently selected by China Business Media as one of China's Top 10 most competitive companies listed overseas for 2009.
The announcement was made at the 2009 China Business Annual Meeting on Enterprise Competitiveness.
The Research Center of Chinese Industries and Enterprise Competitiveness and China Business Media have developed a "competitiveness model" to evaluate companies. The model is based on sales revenue, net assets, net profits, growth rate of net profits, and return on net assets in the past three years.
For the past few years, Sinovac's hepatitis B vaccine, Healive has delivered most of the company's revenues. That changed this year. The company developed a seasonal flu vaccine, Anflu, and then a pandemic flu vaccine, Panflu, which China's national and local governments supplied to their populations. As a result, Sinovac's two flu vaccines will provide a large boost to the company's fortunes this year.